IITF 2026 - EPFO Lounge & ESIC Pavilion inaugurated (See 'Corp Brief') Giriraj Singh visits Welspun World's State-of-the-Art Manufacturing Units in Kutch (See 'Corp Brief') PMLA - Status of secured creditor & initiation of prior recovery proceedings under SARFAESI Act do not exempt a property from attachment under PMLA, when property constitutes proceeds of crime: SAFEMA Tribunal (See 'Legal Desk') Indian Business leaders and Start ups to participate in the India-Egypt Business Forum (See 'Corp Brief') NRIDA selected for Medal for Innovation in Road Technology (See 'Corp Brief') PMLA - Objectives of special anti-money laundering law supersede private commercial security interests - properties linked to criminal activities liable to provisional & final attachment: SAFEMA Tribunal (See 'Legal Desk') Shilp Samagam Mela 2026 at Dilli Haat records Cumulative Sales of Over Rs 88.36 Lakh (See 'Corp Brief') National Tribal Literary Festival concludes with Emphasis on Preserving Oral Traditions (See 'Corp Brief') SEBI - Freezing the Appellants' demat & bank accounts pending deposit of alleged unlawful gains of Rs. 28.12 crore, is valid: SAT (See 'Legal Desk') MoS calls for strengthening India-Italy collaborative research for innovation (See 'Corp Brief') Ministry of Culture invites Partners to Build India's Creative Economy Together (See 'Corp Brief') DoT organises First All India Conference on Official Language 2026 in New Delhi (See 'Corp Brief') Centre strengthens healthcare network through 3 Urban Primary Health Centres (See 'Corp Brief') TDB-DST signs agreement with Astrome to develop sovereign space-based AI-ELINT constellation (See 'Corp Brief') 2nd Edition of the National Tribal Literary Festival 2026 begins in New Delhi (See 'Corp Brief') CCRAS-CARI and University of Delhi sign MoU to document medicinal plant diversity (See 'Corp Brief') RTI - Per Sections 2 & 3 of the Act, CPIO is not obligated to compile, analyze, correlate, or generate fresh datasets from disparate records in specific format desired by applicant: IBBI (See 'Legal Desk') Naturopathy Day 2026: Scientific Research strengthens India's Nature-Based Healthcare Ecosystem (See 'Corp Brief') India and Italy to deepen scientific cooperation through bilateral engagements (See 'Corp Brief') Yadav holds interaction with LeadIT Industry Members and Project Partners (See 'Corp Brief') SEBI - Stay on 5-year debarrment unwarranted where Appellant fails to make out prima facie case - unusual trading pattern noted along with admitted receipt of certain funds from connected entities: SAT (See 'Legal Desk') India strengthens Regional Health Partnerships as First BIMSTEC summit (See 'Corp Brief') CBN dismantles clan lab of mephedrone in Uttar Pradesh (See 'Corp Brief') IPR - Dominant element of composite mark is entitled to standalone protection and party cannot resile from concession made on court record without seeking formal recall of order: HC (See 'Legal Desk') An unsuccessful 'success fee' litigation (See CORP EINSICHT)

Govt hosts workshop on increasing R&D in pharma-medical tech sector

Published: Mar 13, 2025

By TIOLCorplaws News Service

NEW DELHI, MAR 13, 2025: THE Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, organised a workshop on the Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) Scheme today. The workshop was inaugurated in the presence of the Secretaries of five stakeholder Ministries and Departments of the Government of India, namely, Amit Agrawal, Secretary, Department of Pharmaceuticals; Prof. Abhay Karandikar, Secretary, Department of Science and Technology (DST); S. Krishnan, Secretary, Ministry of Electronics and Information Technology (MeitY); Dr N. Kalaiselvi, Secretary, Department of Scientific and Industrial Research (DSIR) and Director General (DG), Council of Scientific and Industrial Research (CSIR); and Dr Rajiv Bahl, Secretary, Department of Health Research (DHR) and DG, Indian Council for Medical Research (ICMR). The workshop served as a platform for identifying key action points and approaches to further the shared commitment to promote research and development in the pharmaceuticals and medical technologies sector.

Amit Agrawal, Secretary, Department of Pharmaceuticals highlighted the rapid expansion in the sector, underscoring the importance of research and innovation in driving making and innovating in India for India and the world. In this regard, he highlighted that the global share of personalised and precision technology platforms (such as antibody-drug conjugates, bi-specific antibodies, and cell and gene therapy) among the top-100 drugs by value is growing rapidly, from 5% in 2020 to 9% in 2025 and projected to grow to 20% by 2030. He also highlighted the 10 times increase in the number of Indian healthcare and life sciences startups over the last four years, from over 900 in 2020 to more than 10,000 in 2024, as well as the growing pipeline of innovative products of Indian firms.

Amit Agrawal said that the groundwork and the pipeline for projects for the PRIP scheme has been laid through this growing innovation ecosystem of Indian startups and industry, supported by a wide array of initiatives of the scientific Ministries/ Departments. The latter include the clinical trial network created by CSIR under its INTENT initiative; the patenting support available through DST's TIFAC and ICMR's Patent Mitra initiative; the handholding support available to both medical technology and drug innovations through ICMR's MedTech Mitra initiative; the funding support available to startups through Department of Biotechnology's BIRAC, MeitY's TIDE 2.0 and SAMRIDH schemes and DST's Quantum Computing Mission, etc.

Reiterating the Government's commitment to a robust research ecosystem, Amit said that PRIP is a transformative initiative aimed at catalysing innovation, strengthening industry-academia linkages, and positioning India as a global leader in pharmaceutical and MedTech research.

Prof. Abhay Karandikar, Secretary, DST underscored the importance of cutting-edge scientific research in driving advancements in pharmaceuticals and MedTech, reinforcing India's healthcare ecosystem and highlighted the supports available through the extensive incubator and accelerator network of DST.

S. Krishnan, Secretary, MeitY emphasised the transformative potential of digital health, artificial intelligence (AI) and data-driven technologies in drug discovery and medical device development. He highlighted the research strengths of MeitY's organisations, such as Society for Applied Microwave Electronics Engineering and Research (SAMEER), C-DAC and Centre for Materials for Electronics Technology (C-MET).

Dr Rajiv Bahl, Secretary, DHR and DG, ICMR highlighted the critical role of clinical research, indigenous drug development and regulatory advancements in accelerating pharmaceutical innovation. He offered the full support of the ICMR INTENT, MedTech Mitra and Patent Mitra initiatives in taking forward the shared goals of PRIP scheme. He also said that the industry-academia collaborative research window under the scheme could be of considerable help in taking forward the large volume of intramural and extramural research being funded by ICMR to the market with funding from PRIP and industry involvement.

Dr N. Kalaiselvi, Secretary, DSIR and DG, CSIR underscored the need to foster a culture of scientific collaboration between research institutions and industry to ensure the seamless translation of research into commercially viable applications. She highlighted that considerable research done in CSIR labs could be taken to the market through collaboration with industry and funding from PRIP.

The discussions reaffirmed the Government's vision of transforming India into a global hub for research and innovation in pharmaceuticals and medical technology. The workshop featured four dedicated breakout sessions, bringing together over 100 participants from leading scientific departments and premier institutions, including the National Institutes of Pharmaceutical Education and Research, IITs, CSIR labs and organisations of ICMR, MeitY, DST and Department of Bio technology, along with key government enablers for the ecosystem. Key deliberations covered the emerging trends in pharmaceutical and MedTech research, strategies for translating research into commercially viable products, government support mechanisms to accelerate sectoral growth and flexibilities sought to maximise the impact from the PRIP scheme.

All participants were requested to share their suggestions in the Expression of Interest (EoI) form for the PRIP scheme hosted on the website of the Department of Pharmaceuticals, so that these may be taken into account while taking forward the scheme and enabling participants. The EoI would be open till April 7, 2025.

TIOL CORP SEARCH

TIOL GROUP WEBSITES